Effient Approval Was Prolonged, But FDA Requirements May Help Sponsors
Executive Summary
FDA's approval of Lilly/Daiichi Sankyo's Effient (prasugrel) NDA took longer than either the sponsors or FDA review management liked. Approval took more than a year-and-half to accomplish, with changes occurring to the very last day, July 10
You may also be interested in...
Effient REMS: FDA Role In Intro Grows; No Safe Use Restrictions
FDA is going to be checking to make sure how many physicians Lilly/Daiichi reach in five key medical practice areas during the first two years of the launch of Effient (prasugrel)
Effient REMS: FDA Role In Intro Grows; No Safe Use Restrictions
FDA is going to be checking to make sure how many physicians Lilly/Daiichi reach in five key medical practice areas during the first two years of the launch of Effient (prasugrel)
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: